David A. Siegel Cullinan Oncology, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 17,900 shares of CGEM stock, worth $225,182. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,900
Previous 20,800
13.94%
Holding current value
$225,182
Previous $362,000
17.4%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CGEM
# of Institutions
146Shares Held
67.6MCall Options Held
612KPut Options Held
118K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$96.2 Million19.97% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$72.3 Million3.06% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$44.7 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$43 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.28MShares$41.3 Million1.02% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $574M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...